Floatz logo

Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

Colon Carcinoma

Explore 154 assets in Colon Carcinoma →
Floatz Rating
CCC55/100
Confidence
Indicative
v0.2
Sponsor
John Strickler, M.D.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07224022CT.gov
Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
—Not Yet Recruiting———
NCT05961709CT.gov
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
—Active Not Recruiting———
NCT05864144CT.gov
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
—Active Not Recruiting———
NCT05259696CT.gov
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Colon Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer (this asset)John Strickler, M.D.P2CCC · 55
FloxuridineCity of Hope Medical CenterP2BBB
FluorouracilumAkesoP4BB
OxaliplatinSun Yat-sen UniversityP3BB
PertuzumabIFOM ETS - The AIRC Institute of Molecular OncologyP3BB
EncorafenibFondazione Policlinico Universitario Agostino Gemelli IRCCSP3BB
IrinotecanSCRI Development Innovations, LLCP3BB
TrastuzumabIFOM ETS - The AIRC Institute of Molecular OncologyP3BB
PalbociclibLebanese UniversityP2BB

+42 more in the Colon Carcinoma cohort

Other indications for Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer

IndicationSponsorPhaseRating
Skin Squamous Cell Carcinoma—P3BB · 66
Lung Cancer—P2/3BB · 65
Nonpapillary Renal Cell Carcinoma—P2BB · 65

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer in Colon Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-programmed-cell-death-protein-1-human-monoclonal-regn2810-heavy-chain-disulfide-with-human-monoclonal-regn2810-kappa-chain-dimer-colon-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →